ReviewGenetic and Epigenetic Biomarkers of Colorectal Cancer
Section snippets
Genetic Factors
Approximately a century ago, von Hansemann10 reported abnormal mitoses in cancer cells. Theodor Boveri11 observed that the abnormal condition of chromosomes in sea urchins contributes to tumor formation and proposed that chromosomal abnormalities are fundamental to cancer. Since then, genetic factors have been in the mainstream of cancer research and the expansion of knowledge in this area has improved our understanding of cancer.
Genetic mutations include small changes in nucleotide sequences
Epigenetic Factors
Epigenetic mutations are mitotically heritable modifications to chromosomes that alter gene expression without changing the DNA sequence.20 The processes involved in epigenetics are DNA methylation, histone modification, and chromatin remodeling. Epigenetics was introduced by CH Waddington in 1939,21 and its association with cancer was first published in 1983.22 Many properties of cancer cells, eg, tumor cell heterogeneity and resistance to therapy23 are not explained by genetic events alone.
Biomarkers in Clinical Use
Genetic and epigenetic alterations can be exploited as biomarkers for screening, early detection, diagnosis, prediction, and prognosis. Cancer-specific mutations and abnormal epigenetic modifications can be used to identify individuals at increased risk and to select optimal interventions. Sensitive and noninvasive methods for cancer detection and diagnosis may be developed from molecular knowledge. Drug discovery is driven by molecular knowledge and the metabolic and signaling pathways
Recent Progress in Biomarker Discovery
Independent investigations of several candidate biomarkers show contradicting results. These may be due to a publication bias, lack of standardization, unintended statistical biases in the samples,9 or clinical trials being conducted on heterogeneous patient groups where treatment is likely to be tailored according to the molecular pathology of the cancer.
Conclusion
The promise of personalized medicine is now a reality.61 With the plethora of studies on different genetic and epigenetic markers for diagnosis, prediction, therapeutic decisions, and prognosis, the translation of molecular genetics is a great challenge. Rapid approval of multiple active agents and speedy proposals of new biomarkers and assays have complicated the translational process.47, 73 No single molecular marker can universally detect or predict cancer or treatment regimen.91 Combining
Acknowledgments
The authors thank Dr Megan Hitchins for her critical comments.
References (98)
- et al.
Colorectal cancer
Lancet
(2005) - et al.
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC
Gastroenterology
(1999) - et al.
Genetic and epigenetic alterations as biomarkers for cancer detection, diagnosis and prognosisMolecular
Oncology
(2007) - et al.
A genetic model for colorectal tumorigenesis
Cell
(1990) - et al.
Cytosine methylation and CpG, TpG (CpA) and TpA frequencies
Gene
(2004) - et al.
Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR
Gastroenterology
(2002) - et al.
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status
European Journal of Cancer
(2009) - et al.
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
Ann Oncol
(2008) KRAS mutation screening in colorectal cancer: from paper to practice
Clin Colorectal Cancer
(2010)- et al.
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer
Ann Oncol
(2006)
The multidisciplinary management of gastrointestinal cancerThe use of molecular markers in the diagnosis and treatment of colorectal cancer
Best Pract Res Clin Gastroenterol
Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients
Ann Oncol
Molecular detection of colorectal neoplasia
Gastroenterology
Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer
Clin Gastroenterol Hepatol
Methylation changes in faecal DNA: a marker for colorectal cancer screening?
Lancet
Biomarkers for predicting clinical responses to HDAC inhibitors
Cancer Lett
The genetics and genomics of cancer
Nat Genet Suppl
Global cancer statistics
CA Cancer J Clin
Genetic predisposition to colorectal cancer
Nat Rev Cancer
Hereditary colorectal cancer
N Engl J Med
Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
J Natl Cancer Inst
Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics
Carcinogenesis
Reporting recommendations for tumor marker prognostic studies
J Clin Oncol
Über asymmetrische Zellteilung in Epithelkrebsen und deren biologische Bedeutung
Virchows Arch Path J Anat
Zur frage der entstehung maligner tumoren
The genetics of colorectal cancer
Ann Intern Med
Microsatellite instability in cancer of the proximal colon
Science
Localization of the gene for familial adenomatous polyposis on chromosome 5
Nature
Signaling pathways in intestinal development and cancer
Annu Rev Cell Dev Biol
Genetic alterations during colorectal-tumor development
N Engl J Med
Genetic and epigenetic alterations in colon cancer
Annu Rev Genomics Hum Genet
The history of cancer epigenetics
Nat Rev Cancer
Preliminary notes on the development of the wings in normal and mutant strains of Drosophila
Proc Natl Acad Sci U S A
Hypomethylation distinguishes genes of some human cancers from their normal counterparts
Nature
Epigenetic changes in cancer
Annu Rev Pathol Mech Dis
Epigenetics and cancer without genomic instability
Cell Cycle
Gene silencing in cancer in association with promoter hypermethylation
N Engl J Med
Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome
Nat Genet
Cancer epigenetics comes of age
Nat Genet
Epigenetics in cancer
N Engl J Med
Use of DNA methylation for cancer detection and molecular classification
J Biochem Mol Biol
CpG island methylator phenotype in colorectal cancer
Proc Natl Acad Sci U S A
CpG island methylator phenotype in cancer
Nat Rev Cancer
DNA methylation profiling in cancer
Expert Rev Mol Med
Epigenetic therapy of cancer: past, present and future
Nat Rev Drug Discov
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
Nat Genet
Revised colorectal screening guidelines: joint effort of the American Cancer Society; U.S. Multisociety Task Force on Colorectal Cancer, and American College of Radiology
Radiology
NCCN clinical practice guidelines in oncologyColorectal cancer screening
J Natl Compr Cancer Netw
SEER cancer statistics review, 1975–2007
Cited by (0)
Conflicts of interest The authors disclose no conflicts.
Funding Funding for this work was provided by Cure Cancer Australia Foundation Grant with assistance from Cancer Australia and awarded through the 2009 round of the Priority-driven Collaborative Cancer Research Scheme (630435) and a New South Wales Health Capacity Building Infrastructure Grant.